Simcere Donates HKD 5 Million to Support Hong Kong Fire Rescue Efforts

Simcere Enters Exclusive Licensing Collaboration with Vigonvita for New Indications of Deuterium Hydrobromide Remididevir Against RSV Infection

Simcere to Start Producing Swiss Insomnia Drug in China, Building Manufacturing Capabilities for Global Supply

Simcere's IL-2 Mutant Fusion Protein SIM0278 Entered Phase II Clinical Trial Stage

SIM0609 Doses First Patient in Phase I Clinical Study at Peking University Cancer Hospital

SIM0237 Phase I NMIBC Data Released in an Oral Presentation at SIU2025

Simcere Zaiming and NextCure Announce Expansion of Ongoing Phase 1 Trial of SIM0505 (CDH6 ADC) into the United States

SIM0609, Simcere Zaiming’s CDH17-targeting ADC is approved by the U.S. FDA to enter clinical trials

Achieving Quality Sleep and improving Daytime Function – Daridorexant Launch Celebrated at the 2025 China Sleep Medicine Development Forum

New-generation anti-insomnia drug Daridorexant issues China's first prescription, ushering in a new era of scientific sleep